Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Michigan

Cancer biologic therapy trials in Michigan

67 cancer biologic therapy studies are recruiting participants at sites in 52 cities across Michigan as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Michigan by city

Cities with the most studies recruiting right now.

Every Michigan city with a recruiting study

By research area: Lymphoma (22), Lung Cancer (21), Breast Cancer (12), Melanoma (7), Prostate Cancer (3), Pancreatic Cancer (2).

Ann Arbor (36), Grand Rapids (36), Detroit (32), Ypsilanti (29), Brighton (28), Chelsea (27), Livonia (27), Pontiac (27), Canton (26), Flint (23), Kalamazoo (23), Lansing (23), Traverse City (19), Wyoming (19), Reed City (18), Saint Joseph (18), Battle Creek (17), Niles (17), Dearborn (16), Macomb (15), Saginaw (15), Novi (14), Tawas City (14), Clinton Township (13), West Bloomfield (13), Farmington Hills (12), Escanaba (11), Jackson (11), Royal Oak (11), Warren (11), Clarkston (10), East China Township (10), Grosse Pointe Woods (10), Norton Shores (10), Wyandotte (10), Brownstown (9), Muskegon (9), Troy (9), Southfield (8), Manistique (4), Mount Pleasant (3), Bay City (2), Lapeer (2), Petoskey (2), Alma (1), Alpena (1), Gladwin (1), Madison Heights (1), Midland (1), Mount Clemens (1), Port Huron (1), Sterling Heights (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Michigan

Basic details from each study's public record (the 12 most recently updated of 67). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ann Arbor · Battle Creek · Brighton · and 24 more U.S. locations
    Registry record
    NCT05564377 · updated
  2. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Ann Arbor · Detroit
    Registry record
    NCT06393374 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Michigan on ClinicalTrials.gov.

Lung cancer: recently updated in Michigan

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ann Arbor · Battle Creek · Brighton · and 27 more U.S. locations
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Ann Arbor · Detroit
    Registry record
    NCT06767514 · updated
  3. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Battle Creek · Grand Rapids · Kalamazoo · and 5 more U.S. locations
    Registry record
    NCT07388524 · updated
  4. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Ypsilanti
    Registry record
    NCT06422143 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Michigan on ClinicalTrials.gov.

Prostate cancer: recently updated in Michigan

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ann Arbor · Brighton · Brownstown · and 21 more U.S. locations
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Michigan on ClinicalTrials.gov.

Melanoma: recently updated in Michigan

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ann Arbor · Battle Creek · Brighton · and 16 more U.S. locations
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Michigan on ClinicalTrials.gov.

Lymphoma: recently updated in Michigan

  1. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ann Arbor · Brighton · Canton · and 12 more U.S. locations
    Registry record
    NCT03739814 · updated
  2. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ann Arbor · Grand Rapids · Kalamazoo
    Registry record
    NCT06317662 · updated
  3. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ann Arbor · Battle Creek · Brighton · and 27 more U.S. locations
    Registry record
    NCT06337318 · updated
  4. Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Michigan Rogel Cancer Center
    Recruiting in
    Ann Arbor
    Registry record
    NCT07892027 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Michigan on ClinicalTrials.gov.

Ask about studies in Michigan

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call